About this trial
The recent development and market introduction of small diameter implantable defibrillation leads able to deliver left bundle branch area pacing (LBBAP) has opened the possibility of achieving cardiac resynchronization therapy (CRT) using a single- or dual-chamber implantable-cardioverter defibrillator (ICD). This approach may reduce the number of intracardiac leads required and, consequently, has the potential to lower both procedural and long-term complication rates. However, the integration of these leads into currently recommended CRT strategies remains hypothetical. The FORGE CSP registry will prospectively enroll patients with an indication for CRT in whom implantation of a LBBAP ICD lead is attempted.
Eligibility criteria
Qualifiers
age > 18-year-old
indication for CRT according to current ESC/EHRA guidelines
first-line LBBAP ICD lead implantation attempted
national insurance coverage
Disqualifiers
pregnancy
Trial design
Treatments tested in this trial
- Not listed